Seres, Vera Notch Weekend Wins in C.Diff, Lupus Trials

Seres Therapeutics shared positive results from its Phase III ECOSPOR trial for the prevention of recurrent C. difficile infection. SER-109 is an oral microbiome therapeutic made up of Firmicutes spores, typically found in healthy microbiomes. It is designed to resist the colonization and growth of Clostridioides difficile, thus preventing the recurrence of infection. The SER-109 purification process removes unwanted microbes to reduce pathogen transmission risks that donor screening might not catch.